NCT04647253进行中（未招募）3 期
AGENT IDE: A Prospective, Randomized (2:1), Multicenter Trial to Assess the Safety and Effectiveness of the AgentTM Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
- 试验地点
- 72
- 主要终点
- Number of Participants With Target Lesion Failure
研究概览
简要总结
AGENT IDE is a Prospective, Randomized (2:1), Multicenter Trial. The purpose of this study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter compared to balloon angioplasty (POBA) in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 26 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria
- •Subject must be at least 18 years of age
- •Subject (or legal guardian) understands the trial requirements and the treatment procedures, and provides written informed consent before any trial-specific tests or procedures are performed
- •Subject is eligible for percutaneous coronary intervention (PCI)
- •Subject is willing to comply with all protocol-required follow-up evaluation
- •Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure
- •Angiographic Inclusion Criteria (visual estimate)
- •In-stent restenosis in a lesion previously treated with either a drug-eluting stent or bare metal stent, located in a native coronary artery with a visually estimated reference vessel diameter (RVD) > 2.0 mm and ≤ 4.0 mm.
- •Target lesion length must be < 26 mm (by visual estimate) and must be covered by only one balloon.
- •Target lesion must have visually estimated stenosis > 50% and < 100% in symptomatic patients (>70% and <100% in asymptomatic patients) prior to lesion pre-dilation.
- •Target lesion must be successfully pre-dilated.
- •o Note: Successful predilation/pretreatment refers to dilation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C. Thrombolysis in Myocardial Infarction (TIMI) grade flow in the target lesion must be >2
- •If a non-target lesion is treated, it must be treated first and must be deemed a success.
- •Note: Successful treatment of a non-target lesion is defined as a residual stenosis of ≤ 30% in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician, without the occurrence of prolonged chest pain or ECG changes consistent with MI.
排除标准
- •Subject has other serious medical illness (e.g. cancer, congestive heart failure) that may reduce life expectancy to less than 24 months.
- •Subject has current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc.).
- •Subject has planned procedure that may cause non-compliance with the protocol or confound data interpretation.
- •Subject is participating in another investigational drug or device clinical study that has not reached its primary endpoint.
- •Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure.
- •Woman who is pregnant or nursing. (A pregnancy test must be performed within 7 days prior to the index procedure, except for women who definitely do not have child-bearing potential.)
- •Left ventricular ejection fraction known to be < 25%.
- •Subject had PCI or other coronary interventions within the last 30 days.
- •Planned PCI or CABG after the index procedure.
- •STEMI or QWMI <72h prior to the index procedure.
- •Cardiogenic shock (SBP < 80 mmHg requiring inotropes, IABP or fluid support).
- •Known allergies against paclitaxel or other components of the used medical devices.
- •Known hypersensitivity or contraindication for contrast dye that in the opinion of the investigator cannot be adequately pre-medicated.
- •Intolerance to antiplatelet drugs, anticoagulants required for procedure.
- •Platelet count < 100k/mm3 (risk of bleeding) or > 700k/mm
- •Subject with renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent).
- •Subject has suspected or proven COVID-19 at present or within the past 4 weeks with resolution of symptoms.
- •Angiographic Exclusion Criteria (visual estimate)
- •Target lesion is located within a bifurcation with planned treatment of side branch vessel.
- •Target lesion is located within a saphenous vein or arterial graft.
- •Thrombus present in the target vessel
- •> 50% stenosis of an additional lesion proximal or clinically significant distal (>2.0mm RVD) to the target lesion.
- •Patient with unprotected left main coronary artery disease. (>50% diameter stenosis)
研究组 & 干预措施
Commercially available, PTCA Dilation Catheter
Active Comparator
干预措施: PTCA balloon catheter (Device)
AGENT DCB
Experimental
Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
干预措施: AGENT DCB (Device)
结局指标
主要结局
Number of Participants With Target Lesion Failure
时间窗: 12-month
The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death
次要结局
未报告次要终点
研究者
研究点 (72)
Loading locations...
相似试验
进行中（未招募）
3 期
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion CohortIn-Stent RestenosisNCT06492174Boston Scientific Corporation20
尚未招募
2 期
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine TumorsNeuroendocrine TumorsNCT06764368Beijing Chest Hospital39
已完成
3 期
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)Diabetes Mellitus, Type 2NCT00094770Merck Sharp & Dohme LLC1,172
Unknown
1 期
Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.Atopic DermatitisNCT04615962Seanergy Dermatology Ltd.66
已完成
2 期
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerColorectal CancerNCT00109226Genentech, Inc.